Initial extended resection or neoadjuvant therapy for T4 non-small cell lung cancer-what is the evidence? Review


Authors: Ilonen, I.; Jones, D. R.
Review Title: Initial extended resection or neoadjuvant therapy for T4 non-small cell lung cancer-what is the evidence?
Abstract: Locally advanced non-small cell lung cancer (NSCLC) tumors that invade surrounding structures within the chest (T4) are a heterogeneous group, and, as such, there are no straightforward guidelines for their management. Advances in imaging, invasive mediastinal staging, and neoadjuvant therapies have expanded the role of surgery with curative intent for this patient group and have also diminished the rate of explorative thoracotomies. Unlike for T4 superior sulcus tumors, the use of neoadjuvant therapy for central T4 tumors is not clearly defined. The most important determinants of a successful outcome after surgery are achieving an R0 resection and avoiding incidental pathologic N2 disease. Use of neoadjuvant therapy in this setting may yield better outcomes after surgery, as both of these variables can be altered if the tumor responds to neoadjuvant therapy. Moreover, response to induction therapy has been shown to have prognostic value. © 2018 AME Publishing Company. All Rights Reserved.
Keywords: neoadjuvant therapy; invasion; t4; non-small cell lung cancer (nsclc)
Journal Title: Shanghai Chest
Volume: 2
ISSN: 2521-3768
Publisher: AME Publishing Company  
Date Published: 2018-10-01
Start Page: 4612
Language: English
DOI: 10.21037/shc.2018.09.08
PROVIDER: scopus
PMCID: PMC6258022
PUBMED: 30498811
DOI/URL:
Notes: The MSK Cancer Center Support Grant (P30 CA008748) is acknowledge in the PDF -- Corresponding authors is MSK author: David R. Jones -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. David Randolph Jones
    417 Jones
  2. Ilkka Kalle Petteri Ilonen
    4 Ilonen